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Testicular tumorsAbstract Objective: The aim of this study was to assess the role of positron emission tomogra-
phy/computed tomography (PET/CT) scan in preoperative staging of testicular tumors and there-
fore determining the line of appropriate management.
Patients and methods: During two year duration we prospectively evaluated 34 patients with testic-
ular tumors diagnosed by histopathology after biopsy or orchidectomy. All patients underwent
PET/CT examinations following a preset protocol that included low dose non contrast study, whole
body scanning post 18F-FDG injection and post IV contrast CT scan. The images obtained were
reconstructed using dedicated software and workstations. Results of PET/CT examinations were
compared with histopathology and serum markers.
Results: Out of 34 cases all masses were malignant (germ cell tumors). 20 masses (58.8%) were
diagnosed by histopathology as seminoma subtype while 14 masses (41.2%) were diagnosed as
non seminomatous germ cell tumors (NSGCT) subtype.
There were 16 true positives, 14 true negatives, 2 false positive, and 2 false negative cases. Sensitiv-
ity, specificity, positive predictive value and negative predictive values were 88.9%, 87.5%, 88.9%
and 87.5% respectively.
Conclusion: Positron emission tomography/computed tomography (PET/CT) has a major role in
preoperative staging of testicular tumors and defines the need of post operative adjuvant therapy.
 2016 The Egyptian Society of Radiology andNuclearMedicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Testicular tumors represent the most common non hemato-
logic malignancy in men between 15 and 49 years old (1).
Although the disease is relatively uncommon, the incidence
has more than doubled over the past four decades (2,3). Themedian ages of diagnosis and death are 33 and 41 years,
respectively (4).
Testicular tumors are subdivided into two major categories:
germ cell and stromal tumors. Germ cell tumors (GCTs)
account for 90–95% of all testicular tumors and are the typical
tumor tissue types considered when discussing testicular
cancer. GCTs are further subdivided into seminoma and
nonseminomatous GCT (NSGCT). This division plays a
critical role in determining the approach to treatment.
Table 1 Different pathologies encountered in the study.
Pathology Post
biopsy
Post
orchidectomy
No. (Total) %
Seminoma 0 20 20 58.8
NSGCT 4 10 14 41.2
All 4 30 34 100
446 T.W. KassemSeminoma is an extremely radiosensitive tumor, whereas
NSGCTs respond better to surgical and chemotherapeutic
approaches (4).
Testicular malignancy has one of the most complete and
thorough staging systems among genitourinary cancers. It
combines clinical, pathologic, radiologic, and serum tumor
marker components. Staging typically relies on surgical
pathology of the orchiectomy specimen, tumor markers
before and after orchiectomy (AFP, HCG, and LDH),Fig. 1 35 years old male patient post biopsy of left testicular so
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image showing the active testicular lesion and left para aortic lymph nchest radiography or chest CT, and CT of the abdomen and
pelvis (2).
Whereas surgical pathology determines the T category of
the neoplasm, imaging plays a critical role in determining the
N and M components of testicular tumor staging. N category
is determined by the extent of retroperitoneal lymphadenopa-
thy, and M category describes distant metastases. Roman
numeral stage grouping divides testicular cancer into three
major groups on the basis of TNMS characteristics: tumors
limited to the testis are stage I, those with retroperitoneal
nodal involvement are stage II, and those with distant disease
are stage III (4).
With the advent of improved staging and treatment there
has been a marked decrease in mortality over this time (5).
Recently, Fluorine-18 fluorodeoxyglucose positron emis-
sion tomography (18F-FDG PET) has been used in combina-
tion with computed tomography (CT) to monitor patients
for metastasis or recurrence. While CT is the standard modal-
ity for detection of lymphadenopathy or retroperitonealft tissue mass proven by histopathology to be seminoma. The
GL) was 103 mg/dL. (A) Axial, coronal and sagittal post contrast
sticular lesion showing enlarged left testis with heterogeneously
sagittal post contrast CT images, fused PET/CT images and MIP
st at and above aortic bifurcation, largest and most active one
th SUVmax 8.7 (arrow heads). (C) Whole body coronal MIP PET
ode.
Fig. 2 37 years old male patient post biopsy of right testicular soft tissue mass proven by histopathology to be seminoma. The
administered activity is 366 MBq 18F-FDG, BGL was 97 mg/dL. (a) Axial post contrast CT image, (b)axial MIP PET image, (c) fused
PET/CT image and (d) whole body coronal MIP PET image showing hypermetabolic right testicular mass, SUV max 8.1 (arrows). FDG
avid right iliac bone small lytic lesion, SUV max 4.2 and focal FDG uptake of the central part of the prostate with related hypodensity and
calcifications, and SUVmax 5.4 are also noted.
Staging and management of testicular tumors 447masses, its false negative rates have been reported to be as high
as 30–59% (6,7).
PET/CT being able to identify regions of increased meta-
bolic activity, has improved the detection of tumor at clinical
staging (8,9). PET/CT scanners generate images that couple
the metabolic sensitivity of PET with the precise anatomic
detail of CT (10). FDG PET has the potential to improve clin-
ical staging of testicular tumors (11). Since 60–70% of patients
with stage I non-seminomatous germ cell tumors (NSGCT)
and 80% of stage I seminoma patients do not have occult
metastasis and do not require adjuvant therapy, PET/CT can
reduce the morbidity of testicular tumors if it can identify
which patients need adjuvant treatment (12,13).
PET scanning does not contribute in stage I of germ cell
tumors, but is a possible option for stages II and III, in partic-
ular for defining treatment strategy (14).
The aim of this study was to assess the role of positron
emission tomography/computed tomography (PET/CT) in
preoperative staging of testicular tumors and therefore
determining the line of appropriate management.2. Patients and methods
2.1. Patients
A prospective study of 34 male patients aged 22–56 years (with
mean age of 33 years) presenting to a private specialized med-
ical center with an initial diagnosis of testicular tumor coming
for staging between January 2014 and December 2015 was per-
formed. There were no set criteria for referral other than
histopathologic evidence of primary testicular tumor after
biopsy or orchidectomy. Patients had clinical evaluation
including medical history. Information regarding serum mark-
ers levels, interventional procedures, open surgeries and
histopathology was obtained from all cases.
2.2. Methods
PET/CT scan examination was obtained for each patient.
Twenty-two patients were scanned using a dedicated PET
Fig. 3 29 years old male patient post excision of left testicular seminoma. The administered activity is 440 MBq 18F-FDG, and BGL was
86 mg/dL. (a) Axial post contrast CT images, (b) axial MIP PET images and (c) axial fused PET/CT images showing hypermetabolic left
para-aortic lymph nodes, largest one measures about 1.2 cm with SUVmax 6.5 (arrows).
Fig. 4 22 years old male patient post excision of left testicular seminoma. The administered activity is 407 MBq 18F-FDG, and BGL was
73 mg/dL. (a) Axial post contrast CT images, (b) axial MIP PET images and (c) axial fused PET/CT images showing hypermetabolic
FDG-avid left para-aortic lymph node measuring about 1.5 cm with SUVmax 8.5 (arrows).
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Berlin, Germany), covering an axial field-of-view (FOV) of
15.2 cm and a resolution of 4 mm axially and 3.8 mm transax-
ially at the center. Twelve patients were scanned using
dedicated PET system (Philips 16 Release 3.5.2, the Nether-
lands), axial FOV of 16.2 cm and a resolution of 4 mm in axial
and transaxial directions. After the patients had fasted for at
least 8 h and were hydrated orally, blood glucose levels were
assessed and found to be within normal range in all cases. First
non contrast low dose CT images were obtained for fusion
images. A 306–445 MBq (18F-FDG) was injected and the
patients rested for an uptake period of 50 min in relaxed posi-
tion. After emptying the bladder, PET scans from the nose to
the upper thighs were acquired.
Routine axial imaging, consisting of CT of the chest, abdo-
men and pelvis at 5 mm intervals after intravenous non ionic
contrast administration was performed in all patients after
they finished the PET/CT examination. Lymph nodes larger
than 1 cm in diameter in short axes were considered
pathologic.2.3. Data analysis and interpretation
The raw data were reconstructed using special software and
workstations. Images were reconstructed in coronal and
sagittal multiplanar planes and read visually.
All PET/CT and CT imaging was performed and evaluated
by one staff radiologist with expertise in genitourinary imaging
accompanied by one staff nuclear medicine. SUV values were
compared to background vasculature to determine positivity
and all foci of unphysiologic FDG uptake were considered
indicative of metastatic disease.
For the purposes of calculating sensitivity, specificity and
predictive values, a true positive was confirmed by
histopathology obtained after open surgery or biopsy
(n= 16). True negatives (n= 14) were confirmed by normal
levels of serum tumor markers using the three well estab-
lished markers named a-fetoprotein (AFP), HCG and lactate
dehydrogenase (LDH). False positives (n= 2) and negatives
(n= 2) were also defined by histopathologic findings con-
trary to PET/CT results.
Fig. 5 (a–c) Whole body coronal MIP PET images for three different patients showing no current evidence of metabolically active local
or metastatic disease.
Fig. 6 28 years old male patient post excision of left testicular NSGCT. The administered activity is 370 MBq 18F-FDG, and BGL was
91 mg/dL. (a) Axial post contrast CT image, (b) axial MIP PET image and (c) axial fused PET/CT image showing mild metabolic activity
in two small subcentimeter left inguinal lymph nodes measuring about 1.0 cm in diameter with SUVmax 3.0 (arrows).
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From January 2014 to December 2015, 34 patients were
entered in the study aged on average 33 years (range,
22–56 years).
Out of 34 cases all masses were malignant (germ cell
tumors). 20 masses (58.8%) were diagnosed by histopathology
post orchidectomy as seminoma subtype while 14 masses
(41.2%) were diagnosed post orchidectomy or biopsy as non
seminomatous germ cell tumors (NSGCTs) subtype as listed
in Table 1.There were 16 true positives, 14 true negatives, 2 false pos-
itive, and 2 false negative cases. Sensitivity, specificity, positive
predictive value and negative predictive values were 88.9%,
87.5%, 88.9% and 87.5% respectively. CT and PET/CT find-
ings matched in 30 of 34 patients and differed in 4 patients.
The true positives patients showed active testicular soft tis-
sue masses in 4 patients who performed the examination post
biopsy and histopathology (Figs. 1 and 2), active residual
tissues at the operative bed detected in 2 patients post
orchidectomy, active para aortic lymph nodes in 8 patients
(Figs. 3 and 4), active inguinal lymph nodes in 4 patients
and active hilar lymph nodes in 2 patients. It was noted that
Fig. 7 33 years old male patient post right orchidectomy for NSGCT. The administered activity is 340 MBq 18F-FDG, and BGL was
84 mg/dL. (a and b) Coronal post contrast CT image showing enlarged para-aortic lymph node measuring about 1 cm in short axis with
no significant FDG uptake (arrows), (c) whole body coronal MIP PET image.
Table 2 Lymph nodes involvement in all cases, n (%).
Pathology Lymph Nodes No LNs
Para Aortic Inguinal Hilar
Seminoma (20 patients) 6 (30%) 2 (10%) 2 (10%) 10 (50%)
NSGCT (14 patients) 4 (28.5%) 4 (28.5%) – 6 (43%)
Total (34 patients) 10 (29.4%) 6 (17.6%) 2 (5.9%) 16 (47%)
450 T.W. Kassem10 patients out of 16 true positive cases were diagnosed as
seminomas.
The true negative patients had no evidence of residual
active operative bed masses or active distant lymph nodes
and had within normal serum tumor markers levels (Fig. 5).
The false positive cases occurred in 2 patients who had
enlarged inguinal lymph node(s) turned out to be non specific
in histopathologic examination after biopsy and no malignant
cells were detected (Fig. 6).
The false negative cases occurred in 2 patients who had
multiple para aortic lymph nodes not exceeding 1 cm in diam-
eter in short axis who had open surgery despite negative PET/
CT scans. Histopathology revealed at least one lymph node
containing embryonal carcinoma, confirming a false negative
for PET/CT (Fig. 7).
Nodal metastatic spread was found in 18 patients (53%)
while 16 patients (47%) had negative PET scan for nodal
involvement. Out of 20 cases diagnosed as seminoma, 6
patients (30%) had para aortic active lymph nodes, 2 patients
(10%) had active inguinal lymph nodes, 2 patients (10%)
had active hilar lymph nodes and 10 patients (50%) hadnegative PET scans. Out of 14 cases diagnosed as NSGCT, 4
patients (28.5%) had para aortic active lymph nodes, 4 patients
(28.5%) had active inguinal lymph nodes and 6 patients (43%)
had negative PET scans as listed in Table 2.
4. Discussion
Imaging plays major role in the clinical staging of testicular
germ cell tumors. While CT and CXR have served as the stan-
dards for these evaluations, recent studies have demonstrated
the utility of PET/CT (8). It provides additive information that
may positively impact decision-making (15).
Primary staging of germ cell tumors is important to imple-
ment the plan of treatment and to reduce the potential for
morbidity from this treatment. Unnecessary radiotherapy/
chemotherapy or surgery can be avoided especially in early
stages.
All staging procedures have their limitations. The rising
serum markers after removal of the primary may indicate dis-
ease presence but cannot locate its site. Anatomical staging
techniques particularly CT have severe limitations in the
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30–59% (7).
When planning for this study the decision was taken to per-
form the examination before chemotherapy taking into consid-
eration the findings of Cremerius et al. (11), who described a
high rate of false negative PET scans within 2 weeks following
chemotherapy, a finding that was confirmed by Hain and col-
leagues (9).
The results of current study suggested that PET/CT identi-
fied the sites of disease in both seminomas and NSGCT during
primary staging and has high specificity and positive predictive
accuracy. This agrees with study done by Sterbis and col-
leagues (15).
PET/CT has been shown to identify viable tumor in resid-
ual masses for both NSGCT and seminomas (16,17). In cur-
rent analysis 2 residual malignant masses were detected post
orchidectomy proven by histopathology to be NSGCT. Cre-
merius et al. (11) found a high accuracy for FDG-PET/CT
in masses containing seminomas and this goes with current
study as 10 patients out of 16 true positive cases were con-
firmed by histopathology as seminomas.
The majority of patients with early stage seminoma and
NSGCT do not require adjuvant treatment post operatively.
Therefore 14 true negative cases diagnosed in this analysis
took a significant potential benefit.
Hain et al. (9) reported 10 true positive cases and 16 true
negative cases out of 31 patients and this matches with current
study including 16 true positive cases and 14 true negative
cases out of 34 patients.
There were 2 cases recorded as false negative, and they had
malignant para aortic lymph nodes that could have been trea-
ted with radiotherapy if detected by PET/CT. Fortunately,
these patients chose to go for open surgery. This was a bit dis-
appointing since ideally PET/CT should be capable of limiting
unnecessary operations. Sterbis et al. (15) reported 1 false neg-
ative case out of 49 patients in 6 year duration while current
study included 2 out of 34 patients despite shorter period of
time.
In addition only 2 patients with false positive PET/CT
scans had moderately active inguinal lymph nodes and border-
line high normal serum markers pushing the diagnosis toward
metastatic nodal involvement. This was proven to be false after
histopathology revealing reactive changes and absence of
malignant cells. Sugawara and colleagues (18) were concerned
about the capability of PET/CT to identify metastatic lesions
smaller than 1 cm. The current analysis combining PET and
CT taking benefit of metabolic sensitivity of PET as well as
anatomic accuracy of CT was able to detect small subcentimet-
ric lesions to the extent that two of them turned to be non
malignant reactive nodes.
PET/CT has limitations as registration may be influenced
by artifacts induced by motion or by metallic implants. SUV
levels obtained manually may be subjected to potential mea-
surement errors. Areas with high physiologic activity such as
the liver may obscure small lesions. It is important to recognize
that fusion imaging with PET/CT is not accurate for small
sized nodes. A minimum 2 week waiting period between the
completion of chemotherapy if any and performance of
PET/CT should be accomplished.
The current small study confirms the findings of previous
few studies using 18F-FDG for primary staging; however,further investigations with a larger patient cohort are needed
to further define its role.
In conclusion PET/CT provides valuable data about the
extent of testicular tumor, its local spread, regional as well
as distant lymph nodal involvement and can detect distant
metastasis. It can provide higher level of detection compared
to CT due to anatomical/functional image registration. There-
fore it has a major role in preoperative staging of testicular
tumors and selection of appropriate post operative adjuvant
therapy.
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